IPC will use the information you provide on this form to send you information about psoriasis. You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by emailing info@psoriasiscouncil.org. By clicking the subscribe button, you agree that we may process your information in accordance with our privacy policy . We use Mailchimp as our marketing automation platform. By clicking the subscribe button to submit this form, you also acknowledge the information you provide will be transferred to Mailchimp for processing in accordance with their privacy policy and terms.
In the latest Psoriasis Review IPC's monthly review of the latest news in the field of psoriasis. Read the latest issue
Latest news European Commission approves SKYRIZI® for psoriatic arthritis in adultsNovember 22, 2021The European Commission has approved SKYRIZI® for the treatment of active psoriatic arthritis in adults. Focus on Psoriasis – A Report from the 2021 Virtual EADV CongressNovember 18, 2021The European Academy of Dermatology and Venerelogy 30th Annual Congress (EADV) was packed with science and clinical practice updates. You can download the full report or read a brief look at some of the highlights. PsoProtect Registry Data UpdateNovember 04, 2021PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data and now includes the first 1,272 cases. Update on spesolimab for generalized pustular psoriasisNovember 02, 2021The European Medicines Agency (EMA) has accepted to review Boehringer Ingelheim’s marketing authorization application (MAA) for spesolimab to treat flares in generalised pustular psoriasis (GPP). More News